Staff pick up the pace, packaging products made by Wuhan Hiteck Biological Pharma Co. [Photo/WeChat account of Wuhan Economic and Technological Development Zone]
Wuhan Hiteck Biological Pharma Co, a high-tech biopharmaceutical company based in the Wuhan Economic and Technological Development Zone (WHDZ) -- in Wuhan city in China’s Central Hubei province -- has been pushing hard to get back to work and production resumption, according to the official WeChat account of the WHDZ.
The biopharma company was affected by the coronavirus epidemic, like other corporate residents in the zone.
But the company got official approval to restart on March 11. At present more than 150 employees have returned to work, accounting for about 50 percent of the total number of employees, with the company’s production capacity now restored to 80-90 percent.
According to Chen Huang, general manager of the group, if work had not resumed before March 20, raw materials previously purchased would have expired, with a loss to the company of more than 2 million yuan ($283,000).
Now, thanks to the local government’s efforts, the company was among the first in the zone to resume work and production.
Chen said that while returning to regular work, the company was also actively doing anti-epidemic work.
These days, at the company entrance, there is an intelligent thermometer. Employees' body temperatures are measured and recorded when they enter and leave the company.
The canteen was reconfigured to have tables for only one person, so as to enable diners to keep their distance while eating. The elevators have also been closed and the workers take the stairs instead.
Wuhan Hiteck Biological Pharma Co is a biopharmaceutical company, based on the research, development and production of drugs in the nervous system and oncology.
The company's leading product, Jin Lu Jie -- a nerve growth agent -- has been classified as a national first-class new drug and the group was listed on the Shenzhen Stock Exchange’s Growth Enterprise Market in August 2017.
